



Remdesivir-Gate for COVID-19

Mina T Kelleni^{1,2*}

¹Assistant Professor of Pharmacology, College of Medicine, Minia University, Egypt

²Assistant Professor of Pharmacology, College of Pharmacy, Jouf University, KSA

***Corresponding Author:** Mina T Kelleni, Assistant Professor of Pharmacology, College of Medicine, Minia University, Egypt and Assistant Professor of Pharmacology, College of Pharmacy, Jouf University, KSA.

Received: June 27, 2020

Published: July 01, 2020

© All rights are reserved by **Mina T Kelleni**.

On the 29th of May, I've explained from a pharmacovigilant point of view why remdesivir is least likely to be considered as a safe treatment for COVID-19 patients and I wish to add some other pieces of evidence not mentioned in that rapid response [1].

Remdesivir, an investigational nucleotide analogue, was unfortunately authorized to be tested for COVID-19 based on few laboratory experiments and reports from some compassionate use and case reports without proper analysis of its safety and efficacy [2].

A full-scale clinical trial of remdesivir used for adult patients admitted to hospital for severe COVID-19 has clearly exposed that remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients on placebo. Further, remdesivir was not associated with statistically significant clinical benefits including the time to clinical improvement (hazard ratio 1.23 [95% CI 0.87 - 1.75]). Further, neither a significant mortality difference nor a decrease in viral load over time has been reported as compared to placebo [3].

Keeping in mind that some positive results of remdesivir were doubted, heavily criticized and shown to be incorrect [4]. I totally agree with a Korean perspective that optimism for remdesivir should be avoided for the time being [5] but I wish to add it should be avoided for good soonest for the best interests of our patients.

Conflict of Interests

None.

Funding

None.

Bibliography

1. Kelleni M. "Rapid Response: Remdesivir is least likely to be effective for safe treatment of COVID-19: A pharmacovigilant point of view". *British Medical Journal* 369 (2020): m2097.
2. Nasir M., et al. "Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences". *My-mensingh Medical Journal* 29.2 (2020): 481-487.
3. Wang Y., et al. "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial". *Lancet (London, England)* 395.10236 (2020): 1569-1578.
4. "Compassionate Use of Remdesivir in Covid-19". *New England Journal of Medicine* 382.25 (2020): e101.
5. Yoo JH. "Uncertainty about the Efficacy of Remdesivir on COVID-19". *Journal of Korean Medical Science* 35.23 (2020): e221.

Assets from publication with us

- Prompt Acknowledgement after receiving the article
- Thorough Double blinded peer review
- Rapid Publication
- Issue of Publication Certificate
- High visibility of your Published work

Website: www.actascientific.com

Submit Article: www.actascientific.com/submission.php

Email us: editor@actascientific.com

Contact us: +91 9182824667